Top

Published in:

01-03-2019 | Original Article

Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer

Authors: Can A. Karaca, Ahmet Coker

Published in: Indian Journal of Surgical Oncology | Issue 1/2019

Abstract

Lymph node involvement in pancreatic adenocancer is one of the strongest predictors of prognosis. However, the extent of lymph node dissection is still a matter of debate and number of dissected nodes varies widely among patients. In order to homogenize this diverse group of patients and more accurately predict their prognosis, we aimed to analyze the effect of metastatic lymph node ratio as an independent prognostic factor. We retrospectively analyzed medical recordings of 326 patients with pancreatic cancer who were treated in a tertiary medical oncology center over a 10-year period. Both in univariate and multivariate analyses, metastatic lymph node ratio proved to be a strong predictor of prognosis which was unaffected from heterogeneity of our patient population and can be used to facilitate predict prognosis of patients who underwent lymph node dissection to various extents and with future studies it can emerge as a successful tool for creating prognostic subgroups of the disease.

Buchler MW, Kleeff J, Friess H (2007) Surgical treatment of pancreatic cancer. J Am Coll Surg 205(4 Suppl):S81–S86. https://doi.org/10.1016/j.jamcollsurg.2007.06.332 CrossRefPubMed

Loos M, Kleeff J, Friess H, Buchler MW (2008) Surgical treatment of pancreatic cancer. Ann N Y Acad Sci 1138:169–180. https://doi.org/10.1196/annals.1414.024 CrossRefPubMed

Adams RB, Allen PJ (2009) Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. Ann Surg Oncol 16(7):1745–1750. https://doi.org/10.1245/s10434-009-0410-z CrossRefPubMed

Schwarz RE, Smith DD (2006) Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13(9):1189–1200. https://doi.org/10.1245/s10434-006-9016-x CrossRefPubMed

Sperti C, Pasquali C, Piccoli A, Pedrazzoli S (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21(2):195–200CrossRefPubMed

Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J (1991) Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161(1):120–124 discussion 124-125CrossRefPubMed

Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165(1):68–72 discussion 72-63CrossRefPubMed

Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T (1988) Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208(2):215–220CrossRefPubMedPubMedCentral

Eskander MF, de Geus SW, Kasumova GG, Ng SC, Al-Refaie W, Ayata G, Tseng JF (2016) Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Surgery doi:https://doi.org/10.1016/j.surg.2016.09.032, 161, 968, 976

10.

Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228(4):508–517CrossRefPubMedPubMedCentral

11.

Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236 (3):355–366; discussion 366-358. doi:https://doi.org/10.1097/01.SLA.0000027272.08464.0B

12.

Nimura Y NM, Kato H (2004) Regional versus extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer: a multicenter, prospective, randomized controlled trial HPB 6 (2)

13.

Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ (2005) A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138(4):618–628; discussion 628-630. https://doi.org/10.1016/j.surg.2005.06.044 CrossRefPubMed

14.

Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM, International Study Group on Pancreatic S (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156(3):591–600. https://doi.org/10.1016/j.surg.2014.06.016 CrossRefPubMed

15.

Lee SY, Hwang I, Park YS, Gardner J, Ro JY (2010) Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol 36(6):1461–1467PubMed

16.

Alatengbaolide LD, Li Y, Xu H, Chen J, Wang B, Liu C, Lu P (2013) Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am J Clin Oncol 36(4):325–330. https://doi.org/10.1097/COC.0b013e318246b4e9 CrossRefPubMed

17.

Zhan HX, Xu JW, Wang L, Zhang GY, Hu SY (2015) Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. World J Surg Oncol 13:105. https://doi.org/10.1186/s12957-015-0510-0 CrossRefPubMedPubMedCentral

18.

Berger AC, Watson JC, Ross EA, Hoffman JP (2004) The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 70 (3):235–240; discussion 240

19.

House MG, Gonen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y, Brennan MF, Allen PJ (2007) Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 11(11):1549–1555. https://doi.org/10.1007/s11605-007-0243-7 CrossRefPubMed

20.

Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141(5):610–618. https://doi.org/10.1016/j.surg.2006.12.013 CrossRefPubMed

21.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F (2009) The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13(7):1337–1344. https://doi.org/10.1007/s11605-009-0919-2 CrossRefPubMed

22.

Robinson SM, Rahman A, Haugk B, French JJ, Manas DM, Jaques BC, Charnley RM, White SA (2012) Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. Eur J Surg Oncol 38(4):333–339. https://doi.org/10.1016/j.ejso.2011.12.020 CrossRefPubMed

23.

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210; discussion 1210-1191. https://doi.org/10.1016/j.gassur.2006.08.018 CrossRefPubMed

24.

Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27(3):324–329. https://doi.org/10.1007/s00268-002-6659-z CrossRefPubMed

25.

Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen HC, van de Velde CJ (1999) Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 25(4):368–374. https://doi.org/10.1053/ejso.1999.0659 CrossRefPubMed

26.

Kodera Y, Schwarz RE, Nakao A (2002) Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 195(6):855–864CrossRefPubMed

27.

Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, Pisters PW (2005) Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 140(6):584–589; discussion 589-591. https://doi.org/10.1001/archsurg.140.6.584 CrossRefPubMed

28.

Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernandez-del Castillo C, Warshaw AL, Thayer SP (2013) N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 17(2):257–266. https://doi.org/10.1007/s11605-012-1974-7 CrossRefPubMed

29.

Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J (2008) The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 37(1):19–24. https://doi.org/10.1097/MPA.0b013e31816074c9 CrossRefPubMed

30.

Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM (2008) Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15(1):165–174. https://doi.org/10.1245/s10434-007-9587-1 CrossRefPubMed

Title: Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer
Authors: Can A. Karaca
Ahmet Coker
Publication date: 01-03-2019
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 1/2019
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-018-0824-9

At a glance: The STEP trials

Springer Medicine

Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma

Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review

Completion Thyroidectomy in Differentiated Thyroid Malignancy—A Prospective Analysis

Endometrial Stromal Sarcoma: Case Series with Emphasis on Gross Features

Management Dilemmas of Intraparotid Facial Nerve Schwannoma: Report of Four Cases and Review of Relevant Literature

Pinch-Off Syndrome and Fracture Embolization: a Preventable Complication of TIVADS